"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." New England Journal of Medicine , 2025 (ATTAIN-1 trial) Eli Lilly press release: ATTAIN-2 Phase 3 topline results
Studies show 80% of obese PCOS patients regain regular menstrual cycles within 6 months of treatment
We performed a stepwise linear regression analysis for each group separately, and for all 41 participants, with age, sex, BMI, HbA 1c , and difference of temperature between cold and hot OGTTs as independent variables
364 Additionally, CT analysis revealed that, compared with their wild-type counterparts, hyperlipidemic rats treated with subcutaneous GLP-1 for 3 days exhibited increased bone mass in the femur and vertebrae
When Mounjaro is introduced, it is important to maintain this monitoring schedule, as changes in metabolic rate associated with thyroid dysfunction can influence blood glucose levels